These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16730098)

  • 1. Long-term administration of PACAP receptor antagonist, PACAP(6-27), impairs glucose tolerance and insulin sensitivity in obese diabetic ob/ob mice.
    Green BD; Irwin N; Cassidy RS; Gault VA; Flatt PR
    Peptides; 2006 Sep; 27(9):2343-9. PubMed ID: 16730098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term administration of maxadilan improves glucose tolerance and insulin sensitivity in mice.
    Yu R; Yi T; Xie S; Hong A
    Peptides; 2008 Aug; 29(8):1347-53. PubMed ID: 18440093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide: effects on insulin release in isolated mouse islets in relation to metabolic status and age.
    Persson-Sjögren S; Forsgren S; Lindström P
    Neuropeptides; 2006 Aug; 40(4):283-90. PubMed ID: 16797701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.
    Green BD; Irwin N; Gault VA; Bailey CJ; O'Harte FP; Flatt PR
    J Endocrinol; 2005 May; 185(2):307-17. PubMed ID: 15845923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of VIP and PACAP in islet function.
    Winzell MS; Ahrén B
    Peptides; 2007 Sep; 28(9):1805-13. PubMed ID: 17559974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16).
    Irwin N; Green BD; Parker JC; Gault VA; O'Harte FP; Flatt PR
    Regul Pept; 2006 Jul; 135(1-2):45-53. PubMed ID: 16675042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N; McClean PL; Flatt PR
    J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary adenylate cyclase-activating peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential.
    Green BD; Irwin N; Flatt PR
    Peptides; 2006 Jun; 27(6):1349-58. PubMed ID: 16406202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes.
    Irwin N; McClean PL; Patterson S; Hunter K; Flatt PR
    Biol Chem; 2009 Jan; 390(1):75-80. PubMed ID: 18937625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The presence and distribution of pituitary adenylate cyclase activating polypeptide and its receptor in the snail Helix pomatia.
    Hernádi L; Pirger Z; Kiss T; Németh J; Mark L; Kiss P; Tamas A; Lubics A; Toth G; Shioda S; Reglodi D
    Neuroscience; 2008 Aug; 155(2):387-402. PubMed ID: 18590802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis.
    Lee YS; Shin S; Shigihara T; Hahm E; Liu MJ; Han J; Yoon JW; Jun HS
    Diabetes; 2007 Jun; 56(6):1671-9. PubMed ID: 17369525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoreactive C-peptide in spontaneous syndromes of obesity and diabetes in mice.
    Flatt PR; Bailey CJ; Hampton SM; Swanston-Flatt SK; Marks V
    Horm Metab Res; 1987 Jan; 19(1):1-5. PubMed ID: 3549500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anorexigenic action of pituitary adenylate cyclase-activating polypeptide (PACAP) in the goldfish: feeding-induced changes in the expression of mRNAs for PACAP and its receptors in the brain, and locomotor response to central injection.
    Matsuda K; Maruyama K; Miura T; Uchiyama M; Shioda S
    Neurosci Lett; 2005 Sep; 386(1):9-13. PubMed ID: 15975713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of adrenal glands in the development of abnormal glucose and insulin homeostasis in genetically obese (ob/ob) mice.
    Bailey CJ; Day C; Bray GA; Lipson LG; Flatt PR
    Horm Metab Res; 1986 Jun; 18(6):357-60. PubMed ID: 3525360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors: distribution and involvement in the secretion of Podarcis sicula adrenal gland.
    Valiante S; Prisco M; Sciarrillo R; De Falco M; Capaldo A; Gay F; Andreuccetti P; Laforgia V; Varano L
    J Endocrinol; 2008 Feb; 196(2):291-303. PubMed ID: 18252952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) on food intake in the goldfish, Carassius auratus.
    Matsuda K; Maruyama K; Nakamachi T; Miura T; Uchiyama M; Shioda S
    Peptides; 2005 Sep; 26(9):1611-6. PubMed ID: 16112400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.
    Irwin N; Montgomery IA; Moffett RC; Flatt PR
    Biochem Pharmacol; 2013 Jan; 85(1):81-91. PubMed ID: 23085436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central administration of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide differentially regulates energy metabolism in chicks.
    Tachibana T; Oikawa D; Adachi N; Boswell T; Furuse M
    Comp Biochem Physiol A Mol Integr Physiol; 2007 May; 147(1):156-64. PubMed ID: 17291802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.